The successful treatment of baby KJ Muldoon with a bespoke CRISPR gene-editing therapy is a triumph of public-funded research and human ingenuity. It proves that the most intractable genetic disorders can be cured when science is directed toward human need rather than market demand. The development of 'INSTALL'—a new method for large-scale DNA insertion—further promises to scale these miracles, offering hope to those with rare diseases that were previously thought incurable. This is the promise of the 'Intelligence Revolution': using AI to unlock massive chemical libraries and identify new weapons against drug-resistant infections like MRSA.

However, this progress is threatened by the predatory logic of the pharmaceutical industry. While researchers at public universities like Bristol and MGH pioneer these breakthroughs, companies like Novo Nordisk and Hims & Hers are engaged in a 'bifurcated market' struggle over the spoils of the GLP-1 (Ozempic/Wegovy) gold rush. The shift from injectables to pills is driven not by clinical superiority, but by the need to capture 'incremental growth' and facilitate broader uptake in primary care settings where high-margin prescriptions can be churned out. The 'one-hit wonder' model of drug development, where a single blockbuster molecule is valued over holistic public health, ensures that the most revolutionary treatments remain accessible only to the wealthy.

Furthermore, the Trump administration’s dismantling of international medical cooperation, such as the pressure campaign to eliminate Cuba’s medical missions, reveals a willingness to weaponize healthcare for geopolitical gain. Tearing down programs that provide 20% of the medical personnel in some Western Hemisphere countries is a form of soft-power violence. The future of medicine must not be a choice between the miracle of the gene and the extraction of the corporation; it must be a public good, democratically managed and globally shared.